Zhang Xiaofeng,MD

Quick facts

Marketed products

• Tegoprazan 50 mg, tablets, orally, bid
• Tegoprazan 50 mg, tablets, orally, qd · Gastroenterology
  Tegoprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion.

Phase 1 pipeline

• anti-EX02 CAR T cells
• Canagliflozin and Gemcitabine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Zhang Xiaofeng,MD portfolio CI brief
• Zhang Xiaofeng,MD pipeline updates RSS